Abiopharma

News list

(10% Negative) Sanofi (SNY) Announces Clinical Development Update (Form 6-K)

Full text

News bot Oct. 18, 2025, 5:29 p.m.
🌍 Sanofi (SNY) - Form 6-K Filing

Filing Date: 2022-06-13

Accepted: 2022-06-13 14:56:52

Event Type: Clinical Trial Update

Event Details:

Dupixent is first biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood. Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, and significantly reduced itch compared to TCS alone.
💼 Business Developments:
- ✅ Partnership/Collaboration
- ❌ Acquisition Activity: Not reported
- ❌ Licensing Agreement: Not reported
- ✅ Regulatory Milestone
- ❌ Leadership Updates: Not reported
📞 Contact Information:
- Email: sally.bain@sanofi.com